Clinical Trials Directory

Trials / Unknown

UnknownNCT04971447

Extracellular Vesicles and Endothelial Function in Transgender Subjects

Effects of Plasma Extracellular Vesicles on Endothelial Function in Transgender Subjects

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
136 (estimated)
Sponsor
Central Hospital, Nancy, France · Academic / Other
Sex
All
Age
18 Years – 49 Years
Healthy volunteers
Not accepted

Summary

Cardiovascular diseases are the leading cause of mortality. In women, the prevalence of cardiovascular diseases is lower and the presentation of coronary events often atypical. The lack of evidence is related in part to the methodology of studies not considering sex as an essential biological variable. Hormonal treatment is prescribed in transgender subjects to promote the development of sexual characteristics of the desired sex. Early cardiovascular effects of hormonal treatment have been reported in transgender men, while long-term mortality is higher in transgender women. The aim of this project is to study the effects of gender affirming hormonal treatment on arterial stiffness in young transgender subjects followed at the University Hospital of Nancy.

Conditions

Interventions

TypeNameDescription
DRUGgender affirming hormonal treatment in transgender mentestosterone enanthate
DRUGgender affirming hormonal treatment in transgender womenGnRH agonists + estrogen

Timeline

Start date
2022-08-01
Primary completion
2023-09-01
Completion
2024-01-01
First posted
2021-07-21
Last updated
2022-07-25

Source: ClinicalTrials.gov record NCT04971447. Inclusion in this directory is not an endorsement.